FROSCH Stefanie,FROSCH Stefanie,LINZ Klaus,LINZ Klaus,SCHIENE Klaus,SCHIENE Klaus
申请号：
SI201330884
公开号：
SI2852386T1
申请日:
2013.05.16
申请国别(地区):
SI
年份:
2018
代理人:
摘要：
The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is a salicylic acid component selected from the group consisting of acetylsalicylic acid, salicylic acid, salicylamide, ethenzamide, salsalate, dipyrocetyl, benorilate, diflunisal, guacetisal, and the physiologically acceptable salts thereof.
